MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
17.04
-0.11
-0.64%
After Hours: 17.04 0 0.00% 16:32 02/11 EST
OPEN
17.02
PREV CLOSE
17.15
HIGH
17.08
LOW
16.31
VOLUME
352.99K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.12
MARKET CAP
519.14M
P/E (TTM)
11.04
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KROS last week (0202-0206)?
Weekly Report · 2d ago
Weekly Report: what happened at KROS last week (0126-0130)?
Weekly Report · 02/02 10:07
Weekly Report: what happened at KROS last week (0119-0123)?
Weekly Report · 01/26 10:07
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
NASDAQ · 01/19 17:53
Weekly Report: what happened at KROS last week (0112-0116)?
Weekly Report · 01/19 10:12
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
NASDAQ · 01/16 16:15
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
NASDAQ · 01/16 14:08
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
NASDAQ · 01/15 15:26
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.